BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use
NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.
You may also be interested in...
UK HTA body NICE says it is now backing Novartis’s Afinitor for the treatment of some people with advanced kidney cancer on the publicly funded National Health Service after the Swiss group offered a price discount. This changes the availability in England and Wales of the drug, which was previously only available through the controversial Cancer Drugs Fund. NICE has now given the go-ahead for routine commissioning of 13 cancer drugs/indications that were listed on the CDF before it was revamped last year.
The re-launch of the controversial Cancer Drugs Fund in the UK has offered another point for debate about cancer drug pricing, budgetary pressures and the cost of innovation.
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”